PKI-402 – 25 mg

Brand:
Cayman
CAS:
1173204-81-3
Storage:
-20
UN-No:
De Minimis - 3077 / 9

PKI-402 is a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR; IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively).{17757} It reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively) and inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM). PKI-402 (25, 50, and 100 mg/kg) reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model. It also inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models in a dose-dependent manner.{53121}  

 

Available on backorder

SKU: 27664 - 25 mg Category:

Description

A dual inhibitor of PI3K and mTOR (IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively); reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively); inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM); reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model at 25, 50, and 100 mg/kg; inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models


Formal name: N-[4-[3-ethyl-7-(4-morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]phenyl]-N’-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-urea

Synonyms: 

Molecular weight: 570.6

CAS: 1173204-81-3

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling